| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 3.2% | $16.1M | 13.2M | Morgan Stanley | 31 Jul 2025 | |||
| OrbiMed Israel BioFund GP Limited Partnership | 4.8% | $1.18M | 970K | ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP | 18 Jun 2025 | |||
| SPHERA FUNDS MANAGEMENT LTD. | 4.78% | $963K | 900K | Sphera Funds Management Ltd. | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$4.89M | 0 | |
| 2025 Q2 | 4.23M | $4.91M | +$580K | $1.16 | 14 |
| 2025 Q1 | 3.73M | $4.07M | -$472K | $1.09 | 17 |
| 2024 Q4 | 4.16M | $7.53M | -$700K | $1.81 | 16 |
| 2024 Q3 | 4.55M | $7.14M | +$3.02M | $1.57 | 15 |
| 2024 Q2 | 2.67M | $2.44M | +$15.8K | $0.91 | 15 |
| 2024 Q1 | 2.66M | $2.07M | -$36.3K | $0.78 | 14 |
| 2023 Q4 | 2.81M | $1.43M | +$108K | $0.51 | 16 |
| 2023 Q3 | 2.53M | $2.26M | -$524 | $0.90 | 11 |
| 2023 Q2 | 2.53M | $3.33M | -$562K | $1.32 | 10 |
| 2023 Q1 | 2.89M | $4.56M | -$696K | $1.59 | 12 |
| 2022 Q4 | 3.31M | $10.6M | +$240K | $3.20 | 13 |
| 2022 Q3 | 3.25M | $8.09M | -$130K | $2.49 | 13 |
| 2022 Q2 | 3.29M | $12.2M | -$117K | $3.70 | 13 |
| 2022 Q1 | 3.31M | $15.9M | -$114K | $4.80 | 14 |
| 2021 Q4 | 3.29M | $22.7M | +$311K | $6.90 | 14 |
| 2021 Q3 | 3.24M | $35.9M | +$733K | $11.08 | 13 |
| 2021 Q2 | 3.09M | $58.7M | +$1.76M | $19.02 | 11 |
| 2021 Q1 | 2.88M | $82.6M | +$82.6M | $28.74 | 10 |